References

1. 1..
   Duan C, Kuang L, Xiang X, Zhang J, Zhu Y, Wu Y, et al. Drp1 regulates mitochondrial dysfunction and dysregulated metabolism in ischemic injury via Clec16a-, BAX-, and GSH- pathways. Cell Death Dis. 2020;11(4):251.
2. 2..
   Zeng X, Zhang YD, Ma RY, Chen YJ, Xiang XM, Hou DY, et al. Activated Drp1 regulates p62-mediated autophagic flux and aggravates inflammation in cerebral ischemia-reperfusion via the ROS-RIP1/RIP3-exosome axis. Mil Med Res. 2022;9(1):25.
3. 3..
   Friedman JR, Lackner LL, West M, Dibenedetto JR, Nunnari J, Voeltz GK. ER tubules mark sites of mitochondrial division. Science. 2011;334(6054):358–62.
4. 4..
   Hao S, Huang H, Ma RY, Zeng X, Duan CY. Multifaceted functions of Drp1 in hypoxia/ischemia-induced mitochondrial quality imbalance: from regulatory mechanism to targeted therapeutic strategy. Mil Med Res. 2023;10(1):46.
5. 5..
   Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol. 2003;160(2):189–200.
6. 6..
   Cipolat S, Martins De Brito O, Dal Zilio B, Scorrano L. OPA1 requires mitofusin 1 to promote mitochondrial fusion. Proc Natl Acad Sci U S A. 2004;101(45):15927–32.
7. 7..
   Rius-Perez S, Torres-Cuevas I, Millan I, Ortega AL, Perez S. PGC-1α, inflammation, and oxidative stress: an integrative view in metabolism. Oxid Med Cell Longev. 2020;2020:1452696.
8. 8..
   Vercellino I, Sazanov LA. The assembly, regulation and function of the mitochondrial respiratory chain. Nat Rev Mol Cell Biol. 2022;23(2):141–61.
9. 9..
   Martinez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21(10):669–80.
10. 10..
    Garbincius JF, Elrod JW. Mitochondrial calcium exchange in physiology and disease. Physiol Rev. 2022;102(2):893–992.
11. 11..
    Sakamuru S, Zhao J, Attene-Ramos MS, Xia M. Mitochondrial membrane potential assay. Methods Mol Biol. 2022;2474:11–9.
12. 12..
    Duan C, Kuang L, Hong C, Xiang X, Liu J, Li Q, et al. Mitochondrial Drp1 recognizes and induces excessive mPTP opening after hypoxia through BAX-PiC and LRRK2-HK2. Cell Death Dis. 2021;12(11):1050.
13. 13..
    Bonora M, Giorgi C, Pinton P. Molecular mechanisms and consequences of mitochondrial permeability transition. Nat Rev Mol Cell Biol. 2022;23(4):266–85.
14. 14..
    Falabella M, Vernon HJ, Hanna MG, Claypool SM, Pitceathly RDS. Cardiolipin, mitochondria, and neurological disease. Trends Endocrinol Metab. 2021;32(4):224–37.
15. 15..
    Yurista SR, Chong CR, Badimon JJ, Kelly DP, De Boer RA, Westenbrink BD. Therapeutic potential of ketone bodies for patients with cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol. 2021;77(13):1660–9.
16. 16..
    Ng MYW, Wai T, Simonsen A. Quality control of the mitochondrion. Dev Cell. 2021;56(7):881–905.
17. 17..
    Ogor P, Yoshida T, Koike M, Kakizuka A. VCP relocalization limits mitochondrial activity, GSH depletion and ferroptosis during starvation in PC3 prostate cancer cells. Genes Cells. 2021;26(8):570–82.
18. 18..
    Anton A, Mazeaud C, Freppel W, Gilbert C, Tremblay N, Sow AA, et al. Valosin-containing protein ATPase activity regulates the morphogenesis of Zika virus replication organelles and virus-induced cell death. Cell Microbiol. 2021;23(4):e13302.
19. 19..
    Gassen NC, Niemeyer D, Muth D, Corman VM, Martinelli S, Gassen A, et al. SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-coronavirus infection. Nat Commun. 2019;10(1):5770.
20. 20..
    Deshwal S, Fiedler KU, Langer T. Mitochondrial proteases: multifaceted regulators of mitochondrial plasticity. Annu Rev Biochem. 2020;89:501–28.
21. 21..
    Picard M, Shirihai OS. Mitochondrial signal transduction. Cell Metab. 2022;34(11):1620–53.
22. 22..
    Rugarli EI, Langer T. Mitochondrial quality control: a matter of life and death for neurons. EMBO J. 2012;31(6):1336–49.
23. 23..
    Tatsuta T. Protein quality control in mitochondria. J Biochem. 2009;146(4):455–61.
24. 24..
    Wu C, Zhang Z, Zhang W, Liu X. Mitochondrial dysfunction and mitochondrial therapies in heart failure. Pharmacol Res. 2022;175:106038.
25. 25..
    Disatnik MH, Ferreira JC, Campos JC, Gomes KS, Dourado PM, Qi X, et al. Acute inhibition of excessive mitochondrial fission after myocardial infarction prevents long-term cardiac dysfunction. J Am Heart Assoc. 2013;2(5):e000461.
26. 26..
    Ding M, Dong Q, Liu Z, Liu Z, Qu Y, Li X, et al. Inhibition of dynamin-related protein 1 protects against myocardial ischemia-reperfusion injury in diabetic mice. Cardiovasc Diabetol. 2017;16(1):19.
27. 27..
    Zhou H, Wang J, Zhu P, Zhu H, Toan S, Hu S, et al. NR4A1 aggravates the cardiac microvascular ischemia reperfusion injury through suppressing FUNDC1-mediated mitophagy and promoting Mff-required mitochondrial fission by CK2α. Basic Res Cardiol. 2018;113(4):23.
28. 28..
    Marsboom G, Toth PT, Ryan JJ, Hong Z, Wu X, Fang YH, et al. Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circ Res. 2012;110(11):1484–97.
29. 29..
    Lu Z, Li S, Zhao S, Fa X. Upregulated miR-17 regulates hypoxia-mediated human pulmonary artery smooth muscle cell proliferation and apoptosis by targeting mitofusin 2. Med Sci Monit. 2016;22:3301–8.
30. 30..
    Zhu TT, Zhang WF, Luo P, He F, Ge XY, Zhang Z, et al. Epigallocatechin-3-gallate ameliorates hypoxia-induced pulmonary vascular remodeling by promoting mitofusin-2-mediated mitochondrial fusion. Eur J Pharmacol. 2017;809:42–51.
31. 31..
    Yeligar SM, Kang BY, Bijli KM, Kleinhenz JM, Murphy TC, Torres G, et al. PPARγ regulates mitochondrial structure and function and human pulmonary artery smooth muscle cell proliferation. Am J Respir Cell Mol Biol. 2018;58(5):648–57.
32. 32..
    Liu R, Xu C, Zhang W, Cao Y, Ye J, Li B, et al. FUNDC1-mediated mitophagy and HIF1α activation drives pulmonary hypertension during hypoxia. Cell Death Dis. 2022;13(7):634.
33. 33..
    Mokhtari B, Yavari R, Badalzadeh R, Mahmoodpoor A. An overview on mitochondrial-based therapies in sepsis-related myocardial dysfunction: mitochondrial transplantation as a promising approach. Can J Infect Dis Med Microbiol. 2022;2022:3277274.
34. 34..
    Biczo G, Vegh ET, Shalbueva N, Mareninova OA, Elperin J, Lotshaw E, et al. Mitochondrial dysfunction, through impaired autophagy, leads to endoplasmic reticulum stress, deregulated lipid metabolism, and pancreatitis in animal models. Gastroenterology. 2018;154(3):689–703.
35. 35..
    Gukovskaya AS, Gukovsky I, Algul H, Habtezion A. Autophagy, inflammation, and immune dysfunction in the pathogenesis of pancreatitis. Gastroenterology. 2017;153(5):1212–26.
36. 36..
    Llimona F, De Lima TM, Moretti AI, Theobaldo M, Jukemura J, Velasco IT, et al. PGC-1α expression is increased in leukocytes in experimental acute pancreatitis. Inflammation. 2014;37(4):1231–9.
37. 37..
    Schollmeier A, Glitscher M, Hildt E. Relevance of HBx for hepatitis B virus-associated pathogenesis. Int J Mol Sci. 2023;24(5):4964.
38. 38..
    Kim SJ, Khan M, Quan J, Till A, Subramani S, Siddiqui A. Hepatitis B virus disrupts mitochondrial dynamics: induces fission and mitophagy to attenuate apoptosis. PLoS Pathog. 2013;9(12): e1003722.
39. 39..
    Kim S, Kim HY, Lee S, Kim SW, Sohn S, Kim K, et al. Hepatitis B virus X protein induces perinuclear mitochondrial clustering in microtubuleand Dynein-dependent manners. J Virol. 2007;81(4):1714–26.
40. 40..
    Huang XY, Li D, Chen ZX, Huang YH, Gao WY, Zheng BY, et al. Hepatitis B virus X protein elevates Parkin-mediated mitophagy through Lon peptidase in starvation. Exp Cell Res. 2018;368(1):75–83.
41. 41..
    Hino K, Nishina S, Sasaki K, Hara Y. Mitochondrial damage and iron metabolic dysregulation in hepatitis C virus infection. Free Radic Biol Med. 2019;133:193–9.
42. 42..
    Hara Y, Yanatori I, Ikeda M, Kiyokage E, Nishina S, Tomiyama Y, et al. Hepatitis C virus core protein suppresses mitophagy by interacting with parkin in the context of mitochondrial depolarization. Am J Pathol. 2014;184(11):3026–39.
43. 43..
    Fields JA, Serger E, Campos S, Divakaruni AS, Kim C, Smith K, et al. HIV alters neuronal mitochondrial fission/fusion in the brain during HIV-associated neurocognitive disorders. Neurobiol Dis. 2016;86:154–69.
44. 44..
    Rozzi SJ, Avdoshina V, Fields JA, Mocchetti I. Human immunodeficiency virus Tat impairs mitochondrial fission in neurons. Cell Death Discov. 2018;4:8.
45. 45..
    Thangaraj A, Periyasamy P, Liao K, Bendi VS, Callen S, Pendyala G, et al. HIV-1 TAT-mediated microglial activation: role of mitochondrial dysfunction and defective mitophagy. Autophagy. 2018;14(9):1596–619.
46. 46..
    Huang CY, Chiang SF, Lin TY, Chiou SH, Chow KC. HIV-1 Vpr triggers mitochondrial destruction by impairing Mfn2-mediated ER-mitochondria interaction. PLoS One. 2012;7(3):e33657.
47. 47..
    Archer SL, Dasgupta A, Chen KH, Wu D, Baid K, Mamatis JE, et al. SARS-CoV-2 mitochondriopathy in COVID-19 pneumonia exacerbates hypoxemia. Redox Biol. 2022;58: 102508.
48. 48..
    Mehrzadi S, Karimi MY, Fatemi A, Reiter RJ, Hosseinzadeh A. SARS-CoV-2 and other coronaviruses negatively influence mitochondrial quality control: beneficial effects of melatonin. Pharmacol Ther. 2021;224:107825.
49. 49..
    Shang C, Liu Z, Zhu Y, Lu J, Ge C, Zhang C, et al. SARS-CoV-2 causes mitochondrial dysfunction and mitophagy impairment. Front Microbiol. 2021;12:780768.
50. 50..
    Scheele C, Nielsen AR, Walden TB, Sewell DA, Fischer CP, Brogan RJ, et al. Altered regulation of the PINK1 locus: a link between type 2 diabetes and neurodegeneration?. FASEB J. 2007;21(13): 3653–65.
51. 51..
    Cooper ID, Brookler KH, Kyriakidou Y, Elliott BT, Crofts CaP. Metabolic phenotypes and step by step evolution of type 2 diabetes: a new paradigm. Biomedicines. 2021;9(7):800.
52. 52..
    Belosludtsev KN, Starinets VS, Talanov EY, Mikheeva IB, Dubinin MV, Belosludtseva NV. Alisporivir treatment alleviates mitochondrial dysfunction in the skeletal muscles of C57BL/6NCrl mice with high-fat diet/streptozotocin-induced diabetes mellitus. Int J Mol Sci. 2021;22(17):9524.
53. 53..
    Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately down-regulated in human diabetes. Nat Genet. 2003;34(3):267–73.
54. 54..
    Zhu L, Wu X, Liao R. Mechanism and regulation of mitophagy in nonalcoholic fatty liver disease (NAFLD): a mini-review. Life Sci. 2023;312:121162.
55. 55..
    Legaki AI, Moustakas II, Sikorska M, Papadopoulos G, Velliou RI, Chatzigeorgiou A. Hepatocyte mitochondrial dynamics and bioenergetics in obesity-related non-alcoholic fatty liver disease. Curr Obes Rep. 2022;11(3):126–43.
56. 56..
    Heinonen S, Jokinen R, Rissanen A, Pietilainen KH. White adipose tissue mitochondrial metabolism in health and in obesity. Obes Rev. 2020;21(2):e12958.
57. 57..
    Oi M, Donner D, Peart J, Beck B, Wendt L, Headrick JP, et al. Pravastatin improves risk factors but not ischaemic tolerance in obese rats. Eur J Pharmacol. 2018;826:148–57.
58. 58..
    Borengasser SJ, Faske J, Kang P, Blackburn ML, Badger TM, Shankar K. In utero exposure to prepregnancy maternal obesity and postweaning high-fat diet impair regulators of mitochondrial dynamics in rat placenta and offspring. Physiol Genomics. 2014;46(23):841–50.
59. 59..
    Li C, Tan Y, Wu J, Ma Q, Bai S, Xia Z, et al. Resveratrol improves Bnip3-related mitophagy and attenuates high-fat-induced endothelial dysfunction. Front Cell Dev Biol. 2020;8:796.
60. 60..
    Mela V, Ruiz-Limon P, Balongo M, Motahari Rad H, Subiri-Verdugo A, Gonzalez-Jimenez A, et al. Mitochondrial homeostasis in obesity-related hypertriglyceridemia. J Clin Endocrinol Metab. 2022;107(8):2203–15.
61. 61..
    Sharma A, Smith HJ, Yao P, Mair WB. Causal roles of mitochondrial dynamics in longevity and healthy aging. EMBO Rep. 2019;20(12):e48395.
62. 62..
    Weir HJ, Yao P, Huynh FK, Escoubas CC, Goncalves RL, Burkewitz K, et al. Dietary restriction and AMPK increase lifespan via mitochondrial network and peroxisome remodeling. Cell Metab. 2017;26(6):884-96.e5.
63. 63..
    Rana A, Oliveira MP, Khamoui AV, Aparicio R, Rera M, Rossiter HB, et al. Promoting Drp1-mediated mitochondrial fission in midlife prolongs healthy lifespan of Drosophila melanogaster. Nat Commun. 2017;8(1):448.
64. 64..
    Hong X, Isern J, Campanario S, Perdiguero E, Ramirez-Pardo I, Segales J, et al. Mitochondrial dynamics maintain muscle stem cell regenerative competence throughout adult life by regulating metabolism and mitophagy. Cell Stem Cell. 2022;29(10):1506–8.
65. 65..
    Baker N, Wade S, Triolo M, Girgis J, Chwastek D, Larrigan S, et al. The mitochondrial protein OPA1 regulates the quiescent state of adult muscle stem cells. Cell Stem Cell. 2022;29(9):1315–32.e9.
66. 66..
    Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chetelat G, Teunissen CE, et al. Alzheimer’s disease. Lancet. 2021;397(10284): 1577–90.
67. 67..
    Venkataraman AV, Mansur A, Rizzo G, Bishop C, Lewis Y, Kocagoncu E, et al. Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer’s disease. Sci Transl Med. 2022;14(658):eabk1051.
68. 68..
    Manczak M, Kandimalla R, Yin X, Reddy PH. Hippocampal mutant APP and amyloid beta-induced cognitive decline, dendritic spine loss, defective autophagy, mitophagy and mitochondrial abnormalities in a mouse model of Alzheimer’s disease. Hum Mol Genet. 2018;27(8):1332–42.
69. 69..
    Manczak M, Kandimalla R, Fry D, Sesaki H, Reddy PH. Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer’s disease. Hum Mol Genet. 2016;25(23):5148–66.
70. 70..
    Martin-Maestro P, Gargini R, Perry G, Avila J, Garcia-Escudero V. PARK2 enhancement is able to compensate mitophagy alterations found in sporadic Alzheimer’s disease. Hum Mol Genet. 2016;25(4):792–806.
71. 71..
    Malpartida AB, Williamson M, Narendra DP, Wade-Martins R, Ryan BJ. Mitochondrial dysfunction and mitophagy in Parkinson’s disease: from mechanism to therapy. Trends Biochem Sci. 2021;46(4):329–43.
72. 72..
    Eldeeb MA, Thomas RA, Ragheb MA, Fallahi A, Fon EA. Mitochondrial quality control in health and in Parkinson’s disease. Physiol Rev. 2022;102(4):1721–55.
73. 73..
    Wang H, Song P, Du L, Tian W, Yue W, Liu M, et al. Parkin ubiquitinates Drp1 for proteasome-dependent degradation: implication of dysregulated mitochondrial dynamics in Parkinson's disease. J Biol Chem. 2011;286(13):11649–58.
74. 74..
    Li X, Feng Y, Wang XX, Truong D, Wu YC. The critical role of SIRT1 in Parkinson’s disease: mechanism and therapeutic considerations. Aging Dis. 2020;11(6):1608–22.
75. 75..
    Rodrigues T, Ferraz LS. Therapeutic potential of targeting mitochondrial dynamics in cancer. Biochem Pharmacol. 2020;182: 114282.
76. 76..
    Liu Y, Jin M, Wang Y, Zhu J, Tan R, Zhao J, et al. MCU-induced mitochondrial calcium uptake promotes mitochondrial biogenesis and colorectal cancer growth. Signal Transduct Target Ther. 2020;5(1):59.
77. 77..
    Zheng Y, Huang C, Lu L, Yu K, Zhao J, Chen M, et al. STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib. J Hematol Oncol. 2021;14(1):16.
78. 78..
    Kautza B, Gomez H, Escobar D, Corey C, Ataya B, Luciano J, et al. Inhaled, nebulized sodium nitrite protects in murine and porcine experimental models of hemorrhagic shock and resuscitation by limiting mitochondrial injury. Nitric Oxide. 2015;51:7–18.
79. 79..
    Duan C, Kuang L, Xiang X, Zhang J, Zhu Y, Wu Y, et al. Activated Drp1-mediated mitochondrial ROS influence the gut microbiome and intestinal barrier after hemorrhagic shock. Aging (Albany NY). 2020;12(2):1397–416.
80. 80..
    Leskova GF. Phospholipids in mitochondrial dysfunction during hemorrhagic shock. J Bioenerg Biomembr. 2017;49(2):121–9.
81. 81..
    Fauconnier J, Meli AC, Thireau J, Roberge S, Shan J, Sassi Y, et al. Ryanodine receptor leak mediated by caspase-8 activation leads to left ventricular injury after myocardial ischemia-reperfusion. Proc Natl Acad Sci U S A. 2011;108(32):13258–63.
82. 82..
    Granatiero V, De Stefani D, Rizzuto R. Mitochondrial calcium handling in physiology and disease. Adv Exp Med Biol. 2017;982: 25–47.
83. 83..
    Montgomery H. Cardiac reserve: linking physiology and genetics. Intensive Care Med. 2000;26(Suppl 1):S137–44.
84. 84..
    O’brien C, Beaubien-Souligny W, Amsallem M, Denault A, Haddad F. Cardiogenic shock: reflections at the crossroad between perfusion, tissue hypoxia, and mitochondrial function. Can J Cardiol. 2020;36(2):184–96.
85. 85..
    Levy B, Mansart A, Montemont C, Gibot S, Mallie JP, Regnault V, et al. Myocardial lactate deprivation is associated with decreased cardiovascular performance, decreased myocardial energetics, and early death in endotoxic shock. Intensive Care Med. 2007;33(3):495–502.
86. 86..
    Saeb-Parsy K, Martin JL, Summers DM, Watson CJE, Krieg T, Murphy MP. Mitochondria as therapeutic targets in transplantation. Trends Mol Med. 2021;27(2):185–98.
87. 87..
    Chaanine AH, Joyce LD, Stulak JM, Maltais S, Joyce DL, Dearani JA, et al. Mitochondrial morphology, dynamics, and function in human pressure overload or ischemic heart disease with preserved or reduced ejection fraction. Circ Heart Fail. 2019;12(2): e005131.
88. 88..
    Zhou B, Tian R. Mitochondrial dysfunction in pathophysiology of heart failure. J Clin Invest. 2018;128(9):3716–26.
89. 89..
    Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac energy metabolism in heart failure. Circ Res. 2021;128(10):1487–513.
90. 90..
    Wang C, Wang Y, Shen L. Mitochondrial proteins in heart failure: The role of deacetylation by SIRT3. Pharmacol Res. 2021;172: 105802.
91. 91..
    Li Y, Huang D, Jia L, Shangguan F, Gong S, Lan L, et al. LonP1 links mitochondria-ER interaction to regulate heart function. Research (Wash D C). 2023;6:0175.
92. 92..
    Zhou H, Hu S, Jin Q, Shi C, Zhang Y, Zhu P, et al. Mff-dependent mitochondrial fission contributes to the pathogenesis of cardiac microvasculature ischemia/reperfusion injury via induction of mROS-mediated cardiolipin oxidation and HK2/VDAC1 disassociation-involved mPTP opening. J Am Heart Assoc. 2017;6(3):e005328.
93. 93..
    Fan H, He Z, Huang H, Zhuang H, Liu H, Liu X, et al. Mitochondrial quality control in cardiomyocytes: a critical role in the progression of cardiovascular diseases. Front Physiol. 2020;11:252.
94. 94..
    Shimizu Y, Lambert JP, Nicholson CK, Kim JJ, Wolfson DW, Cho HC, et al. DJ-1 protects the heart against ischemia-reperfusion injury by regulating mitochondrial fission. J Mol Cell Cardiol. 2016;97:56–66.
95. 95..
    Cao Y, Xu C, Ye J, He Q, Zhang X, Jia S, et al. Miro2 regulates inter-mitochondrial communication in the heart and protects against TAC-induced cardiac dysfunction. Circ Res. 2019;125(8): 728–43.
96. 96..
    Hu H, Lin Y, Xu X, Lin S, Chen X, Wang S. The alterations of mitochondrial DNA in coronary heart disease. Exp Mol Pathol. 2020;114:104412.
97. 97..
    Ji H, Wang J, Muid D, Song W, Jiang Y, Zhou H. FUNDC1 activates the mitochondrial unfolded protein response to preserve mitochondrial quality control in cardiac ischemia/reperfusion injury. Cell Signal. 2022;92:110249.
98. 98..
    Hong Z, Chen KH, Dasgupta A, Potus F, Dunham-Snary K, Bonnet S, et al. MicroRNA-138 and microRNA-25 down-regulate mitochondrial calcium uniporter, causing the pulmonary arterial hypertension cancer phenotype. Am J Respir Crit Care Med. 2017;195(4):515–29.
99. 99..
    Haslip M, Dostanic I, Huang Y, Zhang Y, Russell KS, Jurczak MJ, et al. Endothelial uncoupling protein 2 regulates mitophagy and pulmonary hypertension during intermittent hypoxia. Arterioscler Thromb Vasc Biol. 2015;35(5):1166–78.
100. 100..
     Dromparis P, Paulin R, Sutendra G, Qi AC, Bonnet S, Michelakis ED. Uncoupling protein 2 deficiency mimics the effects of hypoxia and endoplasmic reticulum stress on mitochondria and triggers pseudohypoxic pulmonary vascular remodeling and pulmonary hypertension. Circ Res. 2013;113(2):126–36.
101. 101..
     James J, Valuparampil Varghese M, Vasilyev M, Langlais PR, Tofovic SP, Rafikova O, et al. Complex III inhibition-induced pulmonary hypertension affects the mitochondrial proteomic landscape. Int J Mol Sci. 2020;21(16):5683.
102. 102..
     Zurlo G, Piquereau J, Moulin M, Pires Da Silva J, Gressette M, Ranchoux B, et al. Sirtuin 1 regulates pulmonary artery smooth muscle cell proliferation: role in pulmonary arterial hypertension. J Hypertens. 2018;36(5):1164–77.
103. 103..
     Zhu Y, Kuang L, Wu Y, Deng H, She H, Zhou Y, et al. Protective effects of inhibition of mitochondrial fission on organ function after sepsis. Front Pharmacol. 2021;12:712489.
104. 104..
     Zhang H, Feng YW, Yao YM. Potential therapy strategy: targeting mitochondrial dysfunction in sepsis. Mil Med Res. 2018;5(1):41.
105. 105..
     Li S, Hu Q, Huang J, Wu X, Ren J. Mitochondria-derived damage-associated molecular patterns in sepsis: from bench to bedside. Oxid Med Cell Longev. 2019;2019:6914849.
106. 106..
     Zhu XX, Zhang WW, Wu CH, Wang SS, Smith FG, Jin SW, et al. The novel role of metabolism-associated molecular patterns in sepsis. Front Cell Infect Microbiol. 2022;12:915099.
107. 107..
     Wang Y, Jasper H, Toan S, Muid D, Chang X, Zhou H. Mitophagy coordinates the mitochondrial unfolded protein response to attenuate inflammation-mediated myocardial injury. Redox Biol. 2021;45:102049.
108. 108..
     Petersen OH, Gerasimenko JV, Gerasimenko OV, Gryshchenko O, Peng S. The roles of calcium and ATP in the physiology and pathology of the exocrine pancreas. Physiol Rev. 2021;101(4): 1691–744.
109. 109..
     Wen L, Voronina S, Javed MA, Awais M, Szatmary P, Latawiec D, et al. Inhibitors of ORAI1 prevent cytosolic calcium-associated injury of human pancreatic acinar cells and acute pancreatitis in 3 mouse models. Gastroenterology. 2015;149(2):481-92.e7.
110. 110..
     Szatmary P, Grammatikopoulos T, Cai W, Huang W, Mukherjee R, Halloran C, et al. Acute pancreatitis: diagnosis and treatment. Drugs. 2022;82(12):1251–76.
111. 111..
     Larsen L, Nielsen TH, Nordstrom CH, Andersen AB, Schierbeck J, Schulz MK, et al. Patterns of cerebral tissue oxygen tension and cytoplasmic redox state in bacterial meningitis. Acta Anaesthesiol Scand. 2019;63(3):329–36.
112. 112..
     Braun JS, Sublett JE, Freyer D, Mitchell TJ, Cleveland JL, Tuomanen EI, et al. Pneumococcal pneumolysin and H₂O₂ mediate brain cell apoptosis during meningitis. J Clin Invest. 2002;109(1):19–27.
113. 113..
     Massari P, Ram S, Macleod H, Wetzler LM. The role of porins in neisserial pathogenesis and immunity. Trends Microbiol. 2003;11(2):87–93.
114. 114..
     Wu T, Jia L, Lei S, Jiang H, Liu J, Li N, et al. Host HSPD1 translocation from mitochondria to the cytoplasm induced by streptococcus suis serovar 2 enolase mediates apoptosis and loss of blood-brain barrier integrity. Cells. 2022;11(13):2071.
115. 115..
     Guerrieri F, Levrero M. HBV, mitochondrial stress, and liver fibrosis: chicken or the egg. Hepatology. 2023;77(4):1088–9.
116. 116..
     Hossain MG, Akter S, Ohsaki E, Ueda K. Impact of the interaction of hepatitis B virus with mitochondria and associated proteins. Viruses. 2020;12(2):175.
117. 117..
     Zheng BY, Fang XF, Zou LY, Huang YH, Chen ZX, Li D, et al. The colocalization of HBx and COXIII upregulates COX-2 promoting HepG2 cell growth. Int J Oncol. 2014;45(3):1143–50.
118. 118..
     Korenaga M, Wang T, Li Y, Showalter LA, Chan T, Sun J, et al. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem. 2005;280(45):37481–8.
119. 119..
     Brault C, Levy PL, Bartosch B. Hepatitis C virus-induced mitochondrial dysfunctions. Viruses. 2013;5(3):954–80.
120. 120..
     Barili V, Fisicaro P, Montanini B, Acerbi G, Filippi A, Forleo G, et al. Targeting p53 and histone methyltransferases restores exhausted CD8⁺ T cells in HCV infection. Nat Commun. 2020;11(1):604.
121. 121..
     Fisicaro P, Barili V, Montanini B, Acerbi G, Ferracin M, Guerrieri F, et al. Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. Nat Med. 2017;23(3):327–36.
122. 122..
     Kim SJ, Syed GH, Khan M, Chiu WW, Sohail MA, Gish RG, et al. Hepatitis C virus triggers mitochondrial fission and attenuates apoptosis to promote viral persistence. Proc Natl Acad Sci U S A. 2014;111(17):6413–8.
123. 123..
     Loureiro D, Tout I, Narguet S, Bed CM, Roinard M, Sleiman A, et al. Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C, or nonalcoholic steatohepatitis. Hepatology. 2023;77(4):1348–65.
124. 124..
     Arnoult D, Petit F, Lelievre JD, Estaquier J. Mitochondria in HIV-1-induced apoptosis. Biochem Biophys Res Commun. 2003;304(3):561–74.
125. 125..
     Fevrier M, Dorgham K, Rebollo A. CD4⁺ T cell depletion in human immunodeficiency virus (HIV) infection: role of apoptosis. Viruses. 2011;3(5):586–612.
126. 126..
     Ohta A, Nishiyama Y. Mitochondria and viruses. Mitochondrion. 2011;11(1):1–12.
127. 127..
     Zheng K, Zheng X, Yang W. The role of metabolic dysfunction in T-cell exhaustion during chronic viral infection. Front Immunol. 2022;13:843242.
128. 128..
     Chang CH, Curtis JD, JrMaggi LB, Faubert B, Villarino AV, O’sullivan D, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell. 2013;153(6):1239–51.
129. 129..
     Kavanagh Williamson M, Coombes N, Juszczak F, Athanasopoulos M, Khan MB, Eykyn TR, et al. Upregulation of glucose uptake and hexokinase activity of primary human CD4⁺ T cells in response to infection with HIV-1. Viruses. 2018;10(3):114.
130. 130..
     Gerriets VA, Rathmell JC. Metabolic pathways in T cell fate and function. Trends Immunol. 2012;33(4):168–73.
131. 131..
     Guo H, Wang Q, Ghneim K, Wang L, Rampanelli E, Holley-Guthrie E, et al. Multi-omics analyses reveal that HIV-1 alters CD4⁺ T cell immunometabolism to fuel virus replication. Nat Immunol. 2021;22(4):423–33.
132. 132..
     Li Q, Wang L, Dong C, Che Y, Jiang L, Liu L, et al. The interaction of the SARS coronavirus non-structural protein 10 with the cellular oxidoreductase system causes an extensive cytopathic effect. J Clin Virol. 2005;34(2):133–9.
133. 133..
     Duan C, Ma R, Zeng X, Chen B, Hou D, Liu R, et al. SARS-CoV-2 achieves immune escape by destroying mitochondrial quality: comprehensive analysis of the cellular landscapes of lung and blood specimens from patients with COVID-19. Front Immunol. 2022;13:946731.
134. 134..
     Rao S, Hoskins I, Tonn T, Garcia PD, Ozadam H, Sarinay Cenik E, et al. Genes with 5’ terminal oligopyrimidine tracts preferentially escape global suppression of translation by the SARS-CoV-2 Nsp1 protein. RNA. 2021;27(9):1025–45.
135. 135..
     Liu XY, Wei B, Shi HX, Shan YF, Wang C. Tom70 mediates activation of interferon regulatory factor 3 on mitochondria. Cell Res. 2010;20(9):994–1011.
136. 136..
     Yoon Y, Galloway CA, Jhun BS, Yu T. Mitochondrial dynamics in diabetes. Antioxid Redox Signal. 2011;14(3):439–57.
137. 137..
     Wei PZ, Szeto CC. Mitochondrial dysfunction in diabetic kidney disease. Clin Chim Acta. 2019;496:108–16.
138. 138..
     Zhang H, Huang Y, Chen S, Tang C, Wang G, Du J, et al. Hydrogen sulfide regulates insulin secretion and insulin resistance in diabetes mellitus, a new promising target for diabetes mellitus treatment? A review J Adv Res. 2021;27:19–30.
139. 139..
     Wang Y, Wang C, Li K, Song X, Yan X, Yu L, et al. Recent advances of nanomedicine-based strategies in diabetes and complications management: diagnostics, monitoring, and therapeutics. J Control Release. 2021;330:618–40.
140. 140..
     Dabravolski SA, Orekhova VA, Baig MS, Bezsonov EE, Starodubova AV, Popkova TV, et al. The role of mitochondrial mutations and chronic inflammation in diabetes. Int J Mol Sci. 2021;22(13):6733.
141. 141..
     Liu Y, Zhang L, Zhang S, Liu J, Li X, Yang K, et al. ATF5 regulates tubulointerstitial injury in diabetic kidney disease via mitochondrial unfolded protein response. Mol Med. 2023;29(1):57.
142. 142..
     De Mello AH, Costa AB, Engel JDG, Rezin GT. Mitochondrial dysfunction in obesity. Life Sci. 2018;192:26–32.
143. 143..
     Chattopadhyay M, Guhathakurta I, Behera P, Ranjan KR, Khanna M, Mukhopadhyay S, et al. Mitochondrial bioenergetics is not impaired in non-obese subjects with type 2 diabetes mellitus. Metabolism. 2011;60(12):1702–10.
144. 144..
     Sookoian S, Flichman D, Scian R, Rohr C, Dopazo H, Gianotti TF, et al. Mitochondrial genome architecture in non-alcoholic fatty liver disease. J Pathol. 2016;240(4):437–49.
145. 145..
     Yi HS. Implications of mitochondrial unfolded protein response and mitokines: a perspective on fatty liver diseases. Endocrinol Metab (Seoul). 2019;34(1):39–46.
146. 146..
     Alberici LC, Oliveira HCF. Mitochondrial adaptive responses to hypertriglyceridemia and bioactive lipids. Antioxid Redox Signal. 2022;36(13–15):953–68.
147. 147..
     Chen Z, Jin ZX, Cai J, Li R, Deng KQ, Ji YX, et al. Energy substrate metabolism and oxidative stress in metabolic cardiomyopathy. J Mol Med (Berl). 2022;100(12):1721–39.
148. 148..
     Amorim JA, Coppotelli G, Rolo AP, Palmeira CM, Ross JM, Sinclair DA. Mitochondrial and metabolic dysfunction in ageing and age-related diseases. Nat Rev Endocrinol. 2022;18(4):243–58.
149. 149..
     Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell. 2023;186(2):243–78.
150. 150..
     Zhu D, Li X, Tian Y. Mitochondrial-to-nuclear communication in aging: an epigenetic perspective. Trends Biochem Sci. 2022;47(8):645–59.
151. 151..
     Zhou Z, Fan Y, Zong R, Tan K. The mitochondrial unfolded protein response: a multitasking giant in the fight against human diseases. Ageing Res Rev. 2022;81:101702.
152. 152..
     Ashleigh T, Swerdlow RH, Beal MF. The role of mitochondrial dysfunction in Alzheimer’s disease pathogenesis. Alzheimers Dement. 2023;19(1):333–42.
153. 153..
     Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer’s pathology in female mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2009;106(34):14670–5.
154. 154..
     Han J, Park H, Maharana C, Gwon AR, Park J, Baek SH, et al. Alzheimer’s disease-causing presenilin-1 mutations have deleterious effects on mitochondrial function. Theranostics. 2021;11(18):8855–73.
155. 155..
     Panicker N, Ge P, Dawson VL, Dawson TM. The cell biology of Parkinson’s disease. J Cell Biol. 2021;220(4):e202012095.
156. 156..
     Borsche M, Pereira SL, Klein C, Grunewald A. Mitochondria and Parkinson’s disease: clinical, molecular, and translational aspects. J Parkinsons Dis. 2021;11(1):45–60.
157. 157..
     Brandon M, Baldi P, Wallace DC. Mitochondrial mutations in cancer. Oncogene. 2006;25(34):4647–62.
158. 158..
     Zong WX, Rabinowitz JD, White E. Mitochondria and cancer. Mol Cell. 2016;61(5):667–76.
159. 159..
     Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
160. 160..
     Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407(6805):770–6.
161. 161..
     Sainero-Alcolado L, Liano-Pons J, Ruiz-Perez MV, Arsenian-Henriksson M. Targeting mitochondrial metabolism for precision medicine in cancer. Cell Death Differ. 2022;29(7):1304–17.
162. 162..
     Yuan Y, Ju YS, Kim Y, Li J, Wang Y, Yoon CJ, et al. Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nat Genet. 2020;52(3):342–52.
163. 163..
     Inigo JR, Chandra D. The mitochondrial unfolded protein response (UPR^mt): shielding against toxicity to mitochondria in cancer. J Hematol Oncol. 2022;15(1):98.
164. 164..
     Rahman S. Mitochondrial disease in children. J Intern Med. 2020;287(6):609–33.
165. 165..
     Duchen MR. Mitochondria in health and disease: perspectives on a new mitochondrial biology. Mol Aspects Med. 2004;25(4):365–451.
166. 166..
     Wada J, Nakatsuka A. Mitochondrial dynamics and mitochondrial dysfunction in diabetes. Acta Med Okayama. 2016;70(3):151–8.
167. 167..
     Nhu NT, Li Q, Liu Y, Xu J, Xiao SY, Lee SD. Effects of Mdivi-1 on neural mitochondrial dysfunction and mitochondria-mediated apoptosis in ischemia-reperfusion injury after stroke: a systematic review of preclinical studies. Front Mol Neurosci. 2021;14:778569.
168. 168..
     Ong SB, Subrayan S, Lim SY, Yellon DM, Davidson SM, Hausenloy DJ. Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation. 2010;121(18):2012–22.
169. 169..
     Sharp WW, Beiser DG, Fang YH, Han M, Piao L, Varughese J, et al. Inhibition of the mitochondrial fission protein dynamin-related protein 1 improves survival in a murine cardiac arrest model. Crit Care Med. 2015;43(2):e38-47.
170. 170..
     Liu X, Song L, Yu J, Huang F, Li Y, Ma C. Mdivi-1: a promising drug and its underlying mechanisms in the treatment of neurodegenerative diseases. Histol Histopathol. 2022;37(6):505–12.
171. 171..
     Liu R, Wang SC, Li M, Ma XH, Jia XN, Bu Y, et al. An inhibitor of DRP1 (Mdivi-1) alleviates LPS-induced septic AKI by inhibiting NLRP3 inflammasome activation. Biomed Res Int. 2020;2020:2398420.
172. 172..
     Oliver D, Reddy PH. Dynamics of dynamin-related protein 1 in Alzheimer’s disease and other neurodegenerative diseases. Cells. 2019;8(9):961.
173. 173..
     Qi X, Qvit N, Su YC, Mochly-Rosen D. A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J Cell Sci. 2013;126(Pt 3):789–802.
174. 174..
     Joshi AU, Ebert AE, Haileselassie B, Mochly-Rosen D. Drp1/Fis1-mediated mitochondrial fragmentation leads to lysosomal dysfunction in cardiac models of Huntington’s disease. J Mol Cell Cardiol. 2019;127:125–33.
175. 175..
     Tian L, Neuber-Hess M, Mewburn J, Dasgupta A, Dunham-Snary K, Wu D, et al. Ischemia-induced Drp1 and Fis1-mediated mitochondrial fission and right ventricular dysfunction in pulmonary hypertension. J Mol Med (Berl). 2017;95(4):381–93.
176. 176..
     Haileselassie B, Mukherjee R, Joshi AU, Napier BA, Massis LM, Ostberg NP, et al. Drp1/Fis1 interaction mediates mitochondrial dysfunction in septic cardiomyopathy. J Mol Cell Cardiol. 2019;130:160–9.
177. 177..
     Haileselassie B, Joshi AU, Minhas PS, Mukherjee R, Andreasson KI, Mochly-Rosen D. Mitochondrial dysfunction mediated through dynamin-related protein 1 (Drp1) propagates impairment in blood brain barrier in septic encephalopathy. J Neuroinflammation. 2020;17(1):36.
178. 178..
     Joshi AU, Saw NL, Vogel H, Cunnigham AD, Shamloo M, Mochly-Rosen D. Inhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis. EMBO Mol Med. 2018;10(3):e8166.
179. 179..
     Li G, Shen F, Fan Z, Wang Y, Kong X, Yu D, et al. Dynasore improves motor function recovery via inhibition of neuronal apoptosis and astrocytic proliferation after spinal cord injury in rats. Mol Neurobiol. 2017;54(9):7471–82.
180. 180..
     Gao D, Zhang L, Dhillon R, Hong TT, Shaw RM, Zhu J. Dynasore protects mitochondria and improves cardiac lusitropy in Langendorff perfused mouse heart. PLoS One. 2013;8(4):e60967.
181. 181..
     Rovira-Llopis S, Banuls C, Diaz-Morales N, Hernandez-Mijares A, Rocha M, Victor VM. Mitochondrial dynamics in type 2 diabetes: Pathophysiological implications. Redox Biol. 2017;11:637–45.
182. 182..
     Feng ST, Wang ZZ, Yuan YH, Wang XL, Guo ZY, Hu JH, et al. Inhibition of dynamin-related protein 1 ameliorates the mitochondrial ultrastructure via PINK1 and Parkin in the mice model of Parkinson’s disease. Eur J Pharmacol. 2021;907: 174262.
183. 183..
     Liu J, Mu C, Yue W, Li J, Ma B, Zhao L, et al. A diterpenoid derivate compound targets selenocysteine of thioredoxin reductases and induces Bax/Bak-independent apoptosis. Free Radic Biol Med. 2013;63:485–94.
184. 184..
     Yue W, Chen Z, Liu H, Yan C, Chen M, Feng D, et al. A small natural molecule promotes mitochondrial fusion through inhibition of the deubiquitinase USP30. Cell Res. 2014;24(4):482–96.
185. 185..
     Guo Y, Zhang H, Yan C, Shen B, Zhang Y, Guo X, et al. Small molecule agonist of mitochondrial fusion repairs mitochondrial dysfunction. Nat Chem Biol. 2023;19(4):468–77.
186. 186..
     Zacharioudakis E, Agianian B, Kumar Mv V, Biris N, Garner TP, Rabinovich-Nikitin I, et al. Modulating mitofusins to control mitochondrial function and signaling. Nat Commun. 2022;13(1):3775.
187. 187..
     Wei FL, Wang TF, Wang CL, Zhang ZP, Zhao JW, Heng W, et al. Cytoplasmic escape of mitochondrial DNA mediated by Mfn2 downregulation promotes microglial activation via cGas-Sting axis in spinal cord injury. Adv Sci (Weinh). 2024;11(4):e2305442.
188. 188..
     Zhang L, Li DC, Liu LF. Paeonol: pharmacological effects and mechanisms of action. Int Immunopharmacol. 2019;72:413–21.
189. 189..
     Liu C, Han Y, Gu X, Li M, Du Y, Feng N, et al. Paeonol promotes Opa1-mediated mitochondrial fusion via activating the CK2α-Stat3 pathway in diabetic cardiomyopathy. Redox Biol. 2021;46:102098.
190. 190..
     Wang X, Zhu G, Yang S, Wang X, Cheng H, Wang F, et al. Paeonol prevents excitotoxicity in rat pheochromocytoma PC12 cells via down-regulation of ERK activation and inhibition of apoptosis. Planta Med. 2011;77(15):1695–701.
191. 191..
     Wang D, Du Y, Xu H, Pan H, Wang R. Paeonol protects mitochondrial injury and prevents pulmonary vascular remodeling in hypoxia. Respir Physiol Neurobiol. 2019;268: 103252.
192. 192..
     Tayanloo-Beik A, Kiasalari Z, Roghani M. Paeonol ameliorates cognitive deficits in streptozotocin murine model of sporadic Alzheimer’s disease via attenuation of oxidative stress, inflammation, and mitochondrial dysfunction. J Mol Neurosci. 2022;72(2):336–48.
193. 193..
     Zhang LN, Zhou HY, Fu YY, Li YY, Wu F, Gu M, et al. Novel small-molecule PGC-1α transcriptional regulator with beneficial effects on diabetic db/db mice. Diabetes. 2013;62(4):1297–307.
194. 194..
     Satish S, Philipose H, Rosales MaB, Saint-Geniez M. Pharmaceutical induction of PGC-1α promotes retinal pigment epithelial cell metabolism and protects against oxidative damage. Oxid Med Cell Longev. 2018;2018:9248640.
195. 195..
     Xu Y, Kabba JA, Ruan W, Wang Y, Zhao S, Song X, et al. The PGC-1α activator ZLN005 ameliorates ischemia-induced neuronal injury in vitro and in vivo. Cell Mol Neurobiol. 2018;38(4):929–39.
196. 196..
     Wang Z, Fu Z, Wang C, Xu J, Ma H, Jiang M, et al. ZLN005 protects against ischemia-reperfusion-induced kidney injury by mitigating oxidative stress through the restoration of mitochondrial fatty acid oxidation. Am J Transl Res. 2021;13(9):10014–37.
197. 197..
     Li W, Li X, Wang B, Chen Y, Xiao A, Zeng D, et al. ZLN005 protects cardiomyocytes against high glucose-induced cytotoxicity by promoting SIRT1 expression and autophagy. Exp Cell Res. 2016;345(1):25–36.
198. 198..
     Lu Y, Li Z, Zhang S, Zhang T, Liu Y, Zhang L. Cellular mitophagy: mechanism, roles in diseases and small molecule pharmacological regulation. Theranostics. 2023;13(2):736–66.
199. 199..
     Xie C, Zhuang XX, Niu Z, Ai R, Lautrup S, Zheng S, et al. Amelioration of Alzheimer’s disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow. Nat Biomed Eng. 2022;6(1):76–93.
200. 200..
     Moskal N, Riccio V, Bashkurov M, Taddese R, Datti A, Lewis PN, et al. ROCK inhibitors upregulate the neuroprotective Parkin-mediated mitophagy pathway. Nat Commun. 2020;11(1):88.
201. 201..
     Zhang CX, Cheng Y, Liu DZ, Liu M, Cui H, Zhang BL, et al. Mitochondria-targeted cyclosporin A delivery system to treat myocardial ischemia reperfusion injury of rats. J Nanobiotechnology. 2019;17(1):18.
202. 202..
     Li J, Yan Z, Fang Q. A mechanism study underlying the protective effects of cyclosporine-A on lung ischemia-reperfusion injury. Pharmacology. 2017;100(1–2):83–90.
203. 203..
     Lei Y, Peng X, Liu L, Dong Z, Li T. Beneficial effect of cyclosporine A on traumatic hemorrhagic shock. J Surg Res. 2015;195(2):529–40.
204. 204..
     Ottani F, Latini R, Staszewsky L, La Vecchia L, Locuratolo N, Sicuro M, et al. Cyclosporine A in reperfused myocardial infarction: the multicenter, controlled, open-label CYCLE trial. J Am Coll Cardiol. 2016;67(4):365–74.
205. 205..
     Patocka J, Nepovimova E, Kuca K, Wu W. Cyclosporine A: chemistry and toxicity - a review. Curr Med Chem. 2021;28(20):3925–34.
206. 206..
     Garcia-Rivas Gde J, Carvajal K, Correa F, Zazueta C. Ru360, a specific mitochondrial calcium uptake inhibitor, improves cardiac post-ischaemic functional recovery in rats in vivo. Br J Pharmacol. 2006;149(7):829–37.
207. 207..
     Chitturi J, Santhakumar V, Kannurpatti SS. Traumatic brain injury metabolome and mitochondrial impact after early stage Ru360 treatment. Mitochondrion. 2021;57:192–204.
208. 208..
     Di Marco G, Vallese F, Jourde B, Bergsdorf C, Sturlese M, De Mario A, et al. A high-throughput screening identifies MICU1 targeting compounds. Cell Rep. 2020;30(7):2321-31.e6.
209. 209..
     Teschke R. Treatment of drug-induced liver injury biomedicines. 2022;11(1):15.
210. 210..
     Mohanty RR, Padhy BM, Das S, Meher BR. Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence. Eur Rev Med Pharmacol Sci. 2021;25(6):2802–7.
211. 211..
     Smeyne M, Smeyne RJ. Glutathione metabolism and Parkinson’s disease. Free Radic Biol Med. 2013;62:13–25.
212. 212..
     Cho YS. Genipin, an inhibitor of UCP2 as a promising new anticancer agent: a review of the literature. Int J Mol Sci. 2022;23(10):5637.
213. 213..
     Hua J, Zhang Z, Zhang L, Sun Y, Yuan Y. UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells. Cancer Chemother Pharmacol. 2021;88(4):633–42.
214. 214..
     Lu R, Kallenborn-Gerhardt W, Geisslinger G, Schmidtko A. Additive antinociceptive effects of a combination of vitamin C and vitamin E after peripheral nerve injury. PLoS One. 2011;6(12):e29240.
215. 215..
     Amini L, Chekini R, Nateghi MR, Haghani H, Jamialahmadi T, Sathyapalan T, et al. The effect of combined vitamin C and vitamin E supplementation on oxidative stress markers in women with endometriosis: a randomized, triple-blind placebo-controlled clinical trial. Pain Res Manag. 2021;2021:5529741.
216. 216..
     Breuss JM, Atanasov AG, Uhrin P. Resveratrol and its effects on the vascular system. Int J Mol Sci. 2019;20(7):1523.
217. 217..
     Rauf A, Imran M, Butt MS, Nadeem M, Peters DG, Mubarak MS. Resveratrol as an anti-cancer agent: a review. Crit Rev Food Sci Nutr. 2018;58(9):1428–47.
218. 218..
     Ellinghaus P, Heisler I, Unterschemmann K, Haerter M, Beck H, Greschat S, et al. BAY 87–2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I. Cancer Med. 2013;2(5):611–24.
219. 219..
     Schockel L, Glasauer A, Basit F, Bitschar K, Truong H, Erdmann G, et al. Targeting mitochondrial complex I using BAY 87–2243 reduces melanoma tumor growth. Cancer Metab. 2015;3:11.
220. 220..
     Zhang Y, Luo T, Ding X, Chang Y, Liu C, Zhang Y, et al. Inhibition of mitochondrial complex III induces differentiation in acute myeloid leukemia. Biochem Biophys Res Commun. 2021;547:162–8.
221. 221..
     Kim KK, Abelman S, Yano N, Ribeiro JR, Singh RK, Tipping M, et al. Tetrathiomolybdate inhibits mitochondrial complex Ⅳ and mediates degradation of hypoxia-inducible factor-1α in cancer cells. Sci Rep. 2015;5:14296.
222. 222..
     Stuart SD, Schauble A, Gupta S, Kennedy AD, Keppler BR, Bingham PM, et al. A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer Metab. 2014;2(1):4.
223. 223..
     Pardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, et al. A Phase I study of CPI-613 in combination with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia. Clin Cancer Res. 2018;24(9):2060–73.
224. 224..
     Chavez JD, Tang X, Campbell MD, Reyes G, Kramer PA, Stuppard R, et al. Mitochondrial protein interaction landscape of SS-31. Proc Natl Acad Sci U S A. 2020;117(26):15363–73.
225. 225..
     Reid Thompson W, Hornby B, Manuel R, Bradley E, Laux J, Carr J, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. 2021;23(3):471–8.
226. 226..
     Zhu Y, Wang H, Fang J, Dai W, Zhou J, Wang X, et al. SS-31 provides neuroprotection by reversing mitochondrial dysfunction after traumatic brain injury. Oxid Med Cell Longev. 2018;2018:4783602.
227. 227..
     Pekala J, Patkowska-Sokola B, Bodkowski R, Jamroz D, Nowakowski P, Lochynski S, et al. L-carnitine-metabolic functions and meaning in humans life. Curr Drug Metab. 2011;12(7):667–78.
228. 228..
     Wang ZY, Liu YY, Liu GH, Lu HB, Mao CY. l-Carnitine and heart disease. Life Sci. 2018;194:88–97.
229. 229..
     Bastola P, Leiserowitz GS, Chien J. Multiple components of protein homeostasis pathway can be targeted to produce drug synergies with VCP inhibitors in ovarian cancer. Cancers (Basel). 2022;14(12):2949.
230. 230..
     Zhao H, Pan H, Wang H, Chai P, Ge S, Jia R, et al. SKP2 targeted inhibition suppresses human uveal melanoma progression by blocking ubiquitylation of p27. Onco Targets Ther. 2019;12:4297–308.
231. 231..
     Yang Y, Yan W, Liu Z, Wei M. Skp2 inhibitor SKPin C1 decreased viability and proliferation of multiple myeloma cells and induced apoptosis. Braz J Med Biol Res. 2019;52(5):e8412.
232. 232..
     Li P, Chen T, Kuang P, Liu F, Li Z, Liu F, et al. Aurora-A/FOXO3A/SKP2 axis promotes tumor progression in clear cell renal cell carcinoma and dual-targeting Aurora-A/SKP2 shows synthetic lethality. Cell Death Dis. 2022;13(7):606.
233. 233..
     Manafi Shabestari R, Chegeni R, Faranoush M, Zaker F, Safa M. Inhibition of Skp2 enhances doxorubicin-induced cell death in B cell precursor acute lymphoblastic leukemia. Cell Biol Int. 2022;46(6):895–906.
234. 234..
     Wu J, Su HK, Yu ZH, Xi SY, Guo CC, Hu ZY, et al. Skp2 modulates proliferation, senescence and tumorigenesis of glioma. Cancer Cell Int. 2020;20:71.
235. 235..
     Mikamo M, Kitagawa K, Sakai S, Uchida C, Ohhata T, Nishimoto K, et al. Inhibiting Skp2 E3 ligase suppresses bleomycin-induced pulmonary fibrosis. Int J Mol Sci. 2018;19(2):474.
236. 236..
     Ruffilli C, Roth S, Rodrigo M, Boyd H, Zelcer N, Moreau K. Proteolysis targeting chimeras (PROTACs): a perspective on integral membrane protein degradation. ACS Pharmacol Transl Sci. 2022;5(10):849–58.
237. 237..
     Li X, Pu W, Zheng Q, Ai M, Chen S, Peng Y. Proteolysis-targeting chimeras (PROTACs) in cancer therapy. Mol Cancer. 2022;21(1):99.
238. 238..
     Li MX, Yang Y, Zhao Q, Wu Y, Song L, Yang H, et al. Degradation versus inhibition: development of proteolysis-targeting chimeras for overcoming statin-induced compensatory upregulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase. J Med Chem. 2020;63(9):4908–28.
239. 239..
     Lai AC, Toure M, Hellerschmied D, Salami J, Jaime-Figueroa S, Ko E, et al. Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016;55(2):807–10.
240. 240..
     Reyes KR, Zhang L, Zhu X, Jindal T, Deshmukh P, Kouchkovsky ID, et al. Association of biomarkers and outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs). J Clin Oncol. 2023;41(6_suppl):532.
241. 241..
     Douglas C, Lomeli N, Lepe J, Di K, Nandwana NK, Vu T, et al. Discovery and validation of novel LonP1 and proteasome inhibitor in IDH1-R132H malignant astrocytoma models. bioRxiv. 2023; .
242. 242..
     Messner M, Mandl MM, Hackl MW, Reinhardt T, Ardelt MA, Szczepanowska K, et al. Small molecule inhibitors of the mitochondrial ClpXP protease possess cytostatic potential and re-sensitize chemo-resistant cancers. Sci Rep. 2021;11(1):11185.
243. 243..
     Medicherla S, Protter AA, Ma JY, Mangadu R, Almirez R, Koppelman B, et al. Preventive and therapeutic potential of p38 α-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes. J Pharmacol Exp Ther. 2006;318(1):99–107.
244. 244..
     Moses MA, Kim YS, Rivera-Marquez GM, Oshima N, Watson MJ, Beebe KE, et al. Targeting the Hsp40/Hsp70 chaperone axis as a novel strategy to treat castration-resistant prostate cancer. Cancer Res. 2018;78(14):4022–35.
245. 245..
     Zhao S, Wu W, Liao J, Zhang X, Shen M, Li X, et al. Molecular mechanisms underlying the renal protective effects of coenzyme Q10 in acute kidney injury. Cell Mol Biol Lett. 2022;27(1):57.
246. 246..
     Li R, Ren T, Zeng J. Mitochondrial coenzyme Q protects sepsis-induced acute lung injury by activating PI3K/Akt/GSK-3β/mTOR pathway in rats. Biomed Res Int. 2019;2019:5240898.
247. 247..
     Li QW, Yang Q, Liu HY, Wu YL, Hao YH, Zhang XQ. Protective role of coenzyme Q10 in acute sepsis-induced liver injury in BALB/c mice. Biomed Res Int. 2020;2020:7598375.
248. 248..
     Petronilho F, Florentino D, Danielski LG, Vieira LC, Martins MM, Vieira A, et al. Alpha-lipoic acid attenuates oxidative damage in organs after sepsis. Inflammation. 2016;39(1):357–65.
249. 249..
     Yuan H, Wan J, Li L, Ge P, Li H, Zhang L. Therapeutic benefits of the group B3 vitamin nicotinamide in mice with lethal endotoxemia and polymicrobial sepsis. Pharmacol Res. 2012;65(3):328–37.
250. 250..
     Diaz-Castro F, Monsalves-Alvarez M, Rojo LE, Del Campo A, Troncoso R. Mifepristone for treatment of metabolic syndrome: beyond Cushing’s syndrome. Front Pharmacol. 2020;11:429.
251. 251..
     Che X, Wang J, He J, Yu Q, Sun W, Chen S, et al. A new trick for an old dog: the application of mifepristone in the treatment of adenomyosis. J Cell Mol Med. 2020;24(2):1724–37.
252. 252..
     Cue L, Diaz F, Briegel KJ, Patel HH, Raval AP. Periodic estrogen receptor-beta activation: a novel approach to prevent ischemic brain damage. Neurochem Res. 2015;40(10):2009–17.
253. 253..
     Chen KC, Chen CR, Chen CY, Tzou KY, Peng CC, Peng RY. Bicalutamide elicits renal damage by causing mitochondrial dysfunction via ROS damage and upregulation of HIF-1. Int J Mol Sci. 2020;21(9):3400.
254. 254..
     Peng CC, Chen CR, Chen CY, Chen KC, Peng RY. Bicalutamide may enhance kidney injury in diabetes by concomitantly damaging energy production from OXPHOS and glycolysis. Chem Biol Interact. 2022;356:109858.
255. 255..
     Milane L, Dolare S, Jahan T, Amiji M. Mitochondrial nanomedicine: subcellular organelle-specific delivery of molecular medicines. Nanomedicine. 2021;37:102422.
256. 256..
     Jiang Q, Yin J, Chen J, Ma X, Wu M, Liu G, et al. Mitochondria-targeted antioxidants: a step towards disease treatment. Oxid Med Cell Longev. 2020;2020:8837893.
257. 257..
     Zinovkin RA, Zamyatnin AA. Mitochondria-targeted drugs. Curr Mol Pharmacol. 2019;12(3):202–14.
258. 258..
     Mcmanus MJ, Murphy MP, Franklin JL. The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease. J Neurosci. 2011;31(44):15703–15.
259. 259..
     Young ML, Franklin JL. The mitochondria-targeted antioxidant MitoQ inhibits memory loss, neuropathology, and extends lifespan in aged 3xTg-AD mice. Mol Cell Neurosci. 2019;101:103409.
260. 260..
     Hamed M, Logan A, Gruszczyk AV, Beach TE, James AM, Dare AJ, et al. Mitochondria-targeted antioxidant MitoQ ameliorates ischaemia reperfusion injury in kidney transplantation models. Br J Surg. 2021;108(9):1072–81.
261. 261..
     Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O’sullivan JD, Fung V, et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson’s disease. Mov Disord. 2010;25(11):1670–4.
262. 262..
     Pavshintsev VV, Podshivalova LS, Frolova OY, Belopolskaya MV, Averina OA, Kushnir EA, et al. Effects of mitochondrial antioxidant SkQ1 on biochemical and behavioral parameters in a Parkinsonism model in mice. Biochemistry (Mosc). 2017;82(12):1513–20.
263. 263..
     Stefanova NA, Muraleva NA, Skulachev VP, Kolosova NG. Alzheimer’s disease-like pathology in senescence-accelerated OXYS rats can be partially retarded with mitochondria-targeted antioxidant SkQ1. J Alzheimers Dis. 2014;38(3):681–94.
264. 264..
     Stefanova NA, Muraleva NA, Maksimova KY, Rudnitskaya EA, Kiseleva E, Telegina DV, et al. An antioxidant specifically targeting mitochondria delays progression of Alzheimer’s disease-like pathology. Aging (Albany NY). 2016;8(11):2713–33.
265. 265..
     Shabalina IG, Vyssokikh MY, Gibanova N, Csikasz RI, Edgar D, Hallden-Waldemarson A, et al. Improved health-span and lifespan in mtDNA mutator mice treated with the mitochondrially targeted antioxidant SkQ1. Aging (Albany NY). 2017;9(2):315–39.
266. 266..
     Petrov A, Perekhvatova N, Skulachev M, Stein L, Ousler G. SkQ1 ophthalmic solution for dry eye treatment: results of a Phase 2 safety and efficacy clinical study in the environment and during challenge in the controlled adverse environment model. Adv Ther. 2016;33(1):96–115.
267. 267..
     Tucker JM, Townsend DM. Alpha-tocopherol: roles in prevention and therapy of human disease. Biomed Pharmacother. 2005;59(7):380–7.
268. 268..
     Smith RA, Porteous CM, Gane AM, Murphy MP. Delivery of bioactive molecules to mitochondria in vivo. Proc Natl Acad Sci U S A. 2003;100(9):5407–12.
269. 269..
     Trnka J, Blaikie FH, Smith RA, Murphy MP. A mitochondria-targeted nitroxide is reduced to its hydroxylamine by ubiquinol in mitochondria. Free Radic Biol Med. 2008;44(7):1406–19.
270. 270..
     Zhang R, Liu C, Yang L, Ji T, Zhang N, Dong X, et al. NOX2-derived hydrogen peroxide impedes the AMPK/Akt-mTOR signaling pathway contributing to cell death in neuronal cells. Cell Signal. 2022;94:110330.
271. 271..
     Hu H, Li M. Mitochondria-targeted antioxidant mitotempo protects mitochondrial function against amyloid beta toxicity in primary cultured mouse neurons. Biochem Biophys Res Commun. 2016;478(1):174–80.
272. 272..
     Mitchell JB, Degraff W, Kaufman D, Krishna MC, Samuni A, Finkelstein E, et al. Inhibition of oxygen-dependent radiation-induced damage by the nitroxide superoxide dismutase mimic, tempol. Arch Biochem Biophys. 1991;289(1):62–70.
273. 273..
     Tamam H, Park J, Gadalla HH, Masters AR, Abdel-Aleem JA, Abdelrahman SI, et al. Development of liposomal gemcitabine with high drug loading capacity. Mol Pharm. 2019;16(7):2858–71.
274. 274..
     Peng Y, Lu J, Li R, Zhao Y, Hai L, Guo L, et al. Glucose and triphenylphos-phonium co-modified redox-sensitive liposomes to synergistically treat glioma with doxorubicin and lonidamine. ACS Appl Mater Interfaces. 2021;13(23):26682–93.
275. 275..
     Xu Y, Wang S, Chan HF, Liu Y, Li H, He C, et al. Triphenylphosphonium-modified poly(ethylene glycol)-poly(epsilon-caprolactone) micelles for mitochondria-targeted gambogic acid delivery. Int J Pharm. 2017;522(1–2):21–33.
276. 276..
     Lopez V, Villegas MR, Rodriguez V, Villaverde G, Lozano D, Baeza A, et al. Janus mesoporous silica nanoparticles for dual targeting of tumor cells and mitochondria. ACS Appl Mater Interfaces. 2017;9(32):26697–706.
277. 277..
     Battogtokh G, Gotov O, Kang JH, Cho J, Jeong TH, Chimed G, et al. Triphenylphosphine-docetaxel conjugate-incorporated albumin nanoparticles for cancer treatment. Nanomedicine (Lond). 2018;13(3):325–38.
278. 278..
     Kianamiri S, Dinari A, Sadeghizadeh M, Rezaei M, Daraei B, Bahsoun NE, et al. Mitochondria-targeted polyamidoamine dendrimercurcumin construct for hepatocellular cancer treatment. Mol Pharm. 2020;17(12):4483–98.
279. 279..
     Mallick S, Thuy LT, Lee S, Park JI, Choi JS. Liposomes containing cholesterol and mitochondria-penetrating peptide (MPP) for targeted delivery of antimycin A to A549 cells. Colloids Surf B Biointerfaces. 2018;161:356–64.
280. 280..
     Battogtokh G, Cho YY, Lee JY, Lee HS, Kang HC. Mitochondrial-targeting anticancer agent conjugates and nanocarrier systems for cancer treatment. Front Pharmacol. 2018;9:922.
281. 281..
     Kezic A, Spasojevic I, Lezaic V, Bajcetic M. Mitochondria-targeted antioxidants: future perspectives in kidney ischemia reperfusion injury. Oxid Med Cell Longev. 2016;2016:2950503.
282. 282..
     Zhang Y, Kong X, Li M, Yin Y, Lin W. The development of a biotin-guided and mitochondria-targeting fluorescent probe for detecting SO₂ precisely in cancer cells. Talanta. 2021;225:121992.
283. 283..
     Purushothaman B, Choi J, Park S, Lee J, Samson AaS, Hong S, et al. Biotin-conjugated PEGylated porphyrin self-assembled nanoparticles co-targeting mitochondria and lysosomes for advanced chemo-photodynamic combination therapy. J Mater Chem B. 2019;7(1):65–79.
284. 284..
     Lohr KM, Frost B, Scherzer C, Feany MB. Biotin rescues mitochondrial dysfunction and neurotoxicity in a tauopathy model. Proc Natl Acad Sci U S A. 2020;117(52):33608–18.
285. 285..
     Anand RS, Ganesan D, Rajasekaran S, Jayavelu T. Astrocytes resolve ER stress through mitochondrial fusion facilitated by biotin availability. Cell Stress Chaperones. 2020;25(6):945–53.
286. 286..
     Fields M, Marcuzzi A, Gonelli A, Celeghini C, Maximova N, Rimondi E. Mitochondria-targeted antioxidants, an innovative class of antioxidant compounds for neurodegenerative diseases: perspectives and limitations. Int J Mol Sci. 2023;24(4):3739.
287. 287..
     Cong J, Wang X, Zheng X, Wang D, Fu B, Sun R, et al. Dysfunction of natural killer cells by FBP1-induced inhibition of glycolysis during lung cancer progression. Cell Metab. 2018;28(2):243-55 e5.
288. 288..
     Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563–71.
289. 289..
     Ding DC, Shyu WC, Lin SZ. Mesenchymal stem cells. Cell Transplant. 2011;20(1):5–14.
290. 290..
     Islam MN, Das SR, Emin MT, Wei M, Sun L, Westphalen K, et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med. 2012;18(5):759–65.
291. 291..
     Li X, Michaeloudes C, Zhang Y, Wiegman CH, Adcock IM, Lian Q, et al. Mesenchymal stem cells alleviate oxidative stress-induced mitochondrial dysfunction in the airways. J Allergy Clin Immunol. 2018;141(5):1634-45.e5.
292. 292..
     Zhang Y, Yu Z, Jiang D, Liang X, Liao S, Zhang Z, et al. iPSC-MSCs with high intrinsic MIRO1 and sensitivity to TNF-α yield efficacious mitochondrial transfer to rescue anthracycline-induced cardiomyopathy. Stem Cell Reports. 2016;7(4):749–63.
293. 293..
     Zhao L, Hu C, Zhang P, Jiang H, Chen J. Mesenchymal stem cell therapy targeting mitochondrial dysfunction in acute kidney injury. J Transl Med. 2019;17(1):142.
294. 294..
     Zhang K, Jiang Y, Wang B, Li T, Shang D, Zhang X. Mesenchymal stem cell therapy: a potential treatment targeting pathological manifestations of traumatic brain injury. Oxid Med Cell Longev. 2022;2022:4645021.
295. 295..
     Bonafede R, Mariotti R. ALS pathogenesis and therapeutic approaches: the role of mesenchymal stem cells and extracellular vesicles. Front Cell Neurosci. 2017;11:80.
296. 296..
     Wang JL, Ding HR, Pan CY, Shi XL, Ren HZ. Mesenchymal stem cells ameliorate lipid metabolism through reducing mitochondrial damage of hepatocytes in the treatment of post-hepatectomy liver failure. Cell Death Dis. 2021;12(1):111.
297. 297..
     Sil S, Dagur RS, Liao K, Peeples ES, Hu G, Periyasamy P, et al. Strategies for the use of extracellular vesicles for the delivery of therapeutics. J Neuroimmune Pharmacol. 2020;15(3):422–42.
298. 298..
     Xu F, Wu Y, Yang Q, Cheng Y, Xu J, Zhang Y, et al. Engineered extracellular vesicles with SHP2 high expression promote mitophagy for Alzheimer’s disease treatment. Adv Mater. 2022;34(49):e2207107.
299. 299..
     Nicolas-Avila JA, Lechuga-Vieco AV, Esteban-Martinez L, Sanchez-Diaz M, Diaz-Garcia E, Santiago DJ, et al. A Network of macrophages supports mitochondrial homeostasis in the heart. Cell. 2020;183(1):94-109.e23.
300. 300..
     Todkar K, Chikhi L, Desjardins V, El-Mortada F, Pepin G, Germain M. Selective packaging of mitochondrial proteins into extracellular vesicles prevents the release of mitochondrial DAMPs. Nat Commun. 2021;12(1):1971.
301. 301..
     Zhao M, Liu S, Wang C, Wang Y, Wan M, Liu F, et al. Mesenchymal stem cell-derived extracellular vesicles attenuate mitochondrial damage and inflammation by stabilizing mitochondrial DNA. ACS Nano. 2021;15(1):1519–38.
302. 302..
     Dutra Silva J, Su Y, Calfee CS, Delucchi KL, Weiss D, Mcauley DF, et al. Mesenchymal stromal cell extracellular vesicles rescue mitochondrial dysfunction and improve barrier integrity in clinically relevant models of ARDS. Eur Respir J. 2021;58(1): 2002978.
303. 303..
     Xia L, Zhang C, Lv N, Liang Z, Ma T, Cheng H, et al. AdMSC-derived exosomes alleviate acute lung injury via transferring mitochondrial component to improve homeostasis of alveolar macrophages. Theranostics. 2022;12(6):2928–47.
304. 304..
     Mao J, Li C, Wu F, She Z, Luo S, Chen X, et al. MSC-EVs transferring mitochondria and related components: a new hope for the treatment of kidney disease. Front Immunol. 2022;13:978571.
305. 305..
     Cao H, Cheng Y, Gao H, Zhuang J, Zhang W, Bian Q, et al. In vivo Tracking of mesenchymal stem cell-derived extracellular vesicles improving mitochondrial function in renal ischemia-reperfusion injury. ACS Nano. 2020;14(4):4014–26.
306. 306..
     Han D, Zheng X, Wang X, Jin T, Cui L, Chen Z. Mesenchymal stem/stromal cell-mediated mitochondrial transfer and the therapeutic potential in treatment of neurological diseases. Stem Cells Int. 2020;2020:8838046.
307. 307..
     Li X, Zhu Y, Wang Y, Xia X, Zheng JC. Neural stem/progenitor cell-derived extracellular vesicles: a novel therapy for neurological diseases and beyond. MedComm (2020). 2023;4(1):e214.
308. 308..
     Crewe C, Funcke JB, Li S, Joffin N, Gliniak CM, Ghaben AL, et al. Extracellular vesicle-based interorgan transport of mitochondria from energetically stressed adipocytes. Cell Metab. 2021;33(9):1853-68.e11.
309. 309..
     Carles-Fontana R, Heaton N, Palma E, Khorsandi SE. Extracellular vesicle-mediated mitochondrial reprogramming in cancer. Cancers (Basel). 2022;14(8):1865.
310. 310..
     Ikeda G, Santoso MR, Tada Y, Li AM, Vaskova E, Jung JH, et al. Mitochondria-rich extracellular vesicles from autologous stem cell-derived cardiomyocytes restore energetics of ischemic myocardium. J Am Coll Cardiol. 2021;77(8):1073–88.
311. 311..
     Sugiura A, Mclelland GL, Fon EA, Mcbride HM. A new pathway for mitochondrial quality control: mitochondrial-derived vesicles. EMBO J. 2014;33(19):2142–56.
312. 312..
     Peng T, Xie Y, Sheng H, Wang C, Lian Y, Xie N. Mitochondrial-derived vesicles: Gatekeepers of mitochondrial response to oxidative stress. Free Radic Biol Med. 2022;188:185–93.
313. 313..
     D’acunzo P, Kim Y, Ungania JM, Perez-Gonzalez R, Goulbourne CN, Levy E. Isolation of mitochondria-derived mitovesicles and subpopulations of microvesicles and exosomes from brain tissues. Nat Protoc. 2022;17(11):2517–49.
314. 314..
     D’acunzo P, Perez-Gonzalez R, Kim Y, Hargash T, Miller C, Alldred MJ, et al. Mitovesicles are a novel population of extracellular vesicles of mitochondrial origin altered in Down syndrome. Sci Adv. 2021;7(7):eabe5085.
315. 315..
     Zhang TG, Miao CY. Mitochondrial transplantation as a promising therapy for mitochondrial diseases. Acta Pharm Sin B. 2023;13(3):1028–35.
316. 316..
     Hayashida K, Takegawa R, Endo Y, Yin T, Choudhary RC, Aoki T, et al. Exogenous mitochondrial transplantation improves survival and neurological outcomes after resuscitation from cardiac arrest. BMC Med. 2023;21(1):56.
317. 317..
     Cowan DB, Yao R, Akurathi V, Snay ER, Thedsanamoorthy JK, Zurakowski D, et al. Intracoronary delivery of mitochondria to the ischemic heart for cardioprotection. PLoS One. 2016;11(8): e0160889.
318. 318..
     Gollihue JL, Patel SP, Eldahan KC, Cox DH, Donahue RR, Taylor BK, et al. Effects of mitochondrial transplantation on bioenergetics, cellular incorporation, and functional recovery after spinal cord injury. J Neurotrauma. 2018;35(15):1800–18.
319. 319..
     Doulamis IP, Guariento A, Duignan T, Kido T, Orfany A, Saeed MY, et al. Mitochondrial transplantation by intra-arterial injection for acute kidney injury. Am J Physiol Renal Physiol. 2020;319(3):F403–13.
320. 320..
     Shi X, Bai H, Zhao M, Li X, Sun X, Jiang H, et al. Treatment of acetaminophen-induced liver injury with exogenous mitochondria in mice. Transl Res. 2018;196:31–41.
321. 321..
     Shi X, Zhao M, Fu C, Fu A. Intravenous administration of mitochondria for treating experimental Parkinson’s disease. Mitochondrion. 2017;34:91–100.
322. 322..
     Sun CK, Lee FY, Kao YH, Chiang HJ, Sung PH, Tsai TH, et al. Systemic combined melatonin-mitochondria treatment improves acute respiratory distress syndrome in the rat. J Pineal Res. 2015;58(2):137–50.
323. 323..
     Masuzawa A, Black KM, Pacak CA, Ericsson M, Barnett RJ, Drumm C, et al. Transplantation of autologously derived mitochondria protects the heart from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2013;304(7):H966–82.
324. 324..
     Guariento A, Piekarski BL, Doulamis IP, Blitzer D, Ferraro AM, Harrild DM, et al. Autologous mitochondrial transplantation for cardiogenic shock in pediatric patients following ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 2021;162(3):992–1001.
325. 325..
     Fang C, Huang R, Jia L, Cao G, Liu X, Chen W, Liang X. A case of transferring mitochondria from autologous bone mesenchymal stem cells into oocytes resulting in a live baby boy. Chin J Reprod Contracep. 2018;38(11):937–9 (in Chinese).
326. 326..
     Jacoby E, Bar-Yosef O, Gruber N, Lahav E, Varda-Bloom N, Bolkier Y, et al. Mitochondrial augmentation of hematopoietic stem cells in children with single large-scale mitochondrial DNA deletion syndromes. Sci Transl Med. 2022;14(676):eabo3724.